Literature DB >> 15487457

ZAP-70 expression in B-cell hematologic malignancy is not limited to CLL/SLL.

Stephen J Sup1, Rana Domiati-Saad, Todd W Kelley, Roxanne Steinle, Xinyu Zhao, Eric D Hsi.   

Abstract

ZAP-70 is a tyrosine kinase expressed in normal T cells and NK cells. Expression of ZAP-70 has been associated with poor prognosis in B-cell chronic lymphocytic leukemia and might be a surrogate marker for immunoglobin heavy chain (IGH) mutational status in that disease. Little is known about ZAP-70 expression in other hematologic malignant neoplasms. We examined 446 specimens representing a range of hematopoietic malignant neoplasms for ZAP-70 expression by immunohistochemical analysis. As expected, most T cell-lineage disorders and a subset of small lymphocytic lymphomas were positive. IGH mutational status corresponded to ZAP-70 expression in a small subset of small lymphocytic lymphoma cases subjected to sequence analysis. Of note, however, ZAP-70 was expressed in a minority of other types of B-cell lymphomas, including precursor B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, and very rare cases of classic Hodgkin lymphoma. Immunohistochemical analysis represents an alternative method for assessing ZAP-70 expression and reveals that other B-cell malignant neoplasms express ZAP-70.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15487457     DOI: 10.1309/WVQP-VDF8-UF7A-V21X

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  6 in total

1.  Differential and tumor-specific expression of CD160 in B-cell malignancies.

Authors:  Timothy W Farren; Jerome Giustiniani; Feng-Ting Liu; Dimitris A Tsitsikas; Marion G Macey; James D Cavenagh; Heather E Oakervee; David Taussig; Adrian C Newland; Maria Calaminici; Armand Bensussan; Michael Jenner; John G Gribben; Samir G Agrawal
Journal:  Blood       Date:  2011-06-28       Impact factor: 22.113

2.  Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression.

Authors:  Joan H Admirand; Ronald J Knoblock; Kevin R Coombes; Constantine Tam; Ellen J Schlette; William G Wierda; Alessandra Ferrajoli; Susan O'Brien; Michael J Keating; Rajyalakshmi Luthra; L Jeffrey Medeiros; Lynne V Abruzzo
Journal:  Mod Pathol       Date:  2010-07-23       Impact factor: 7.842

3.  Quantitative detection of zeta-chain-associated protein 70 expression in chronic lymphocytic leukemia.

Authors:  Peixuan Zhu; Heba A Degheidy; Gerald E Marti; Shuhong Li; Fatima Abbasi; Adrian Wiestner; Platte Amstutz; Cha-Mei Tang
Journal:  Leuk Lymphoma       Date:  2012-08-14

4.  Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer.

Authors:  Teresa Sadras; Mickaël Martin; Kohei Kume; Mark E Robinson; Supraja Saravanakumar; Gal Lenz; Zhengshan Chen; Joo Y Song; Tanya Siddiqi; Laura Oksa; Anne Marie Knapp; Jevon Cutler; Kadriye Nehir Cosgun; Lars Klemm; Veronika Ecker; Janet Winchester; Dana Ghergus; Pauline Soulas-Sprauel; Friedemann Kiefer; Nora Heisterkamp; Akhilesh Pandey; Vu Ngo; Lili Wang; Hassan Jumaa; Maike Buchner; Jürgen Ruland; Wing-Chung Chan; Eric Meffre; Thierry Martin; Markus Müschen
Journal:  Mol Cell       Date:  2021-04-19       Impact factor: 17.970

Review 5.  Update on extranodal lymphomas. Conclusions of the Workshop held by the EAHP and the SH in Thessaloniki, Greece.

Authors:  E Campo; A Chott; M C Kinney; L Leoncini; C J L M Meijer; C S Papadimitriou; M A Piris; H Stein; S H Swerdlow
Journal:  Histopathology       Date:  2006-04       Impact factor: 5.087

Review 6.  ZAP-70 Shapes the Immune Microenvironment in B Cell Malignancies.

Authors:  Jingyu Chen; Andrew Moore; Ingo Ringshausen
Journal:  Front Oncol       Date:  2020-10-27       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.